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Abstract
Background: Prior data has demonstrated increased mortality in hospitalized patients
with acute heart failure (AHF) and troponin elevation. No data has specifically examined the prognostic significance of troponin elevation in patients with AHF discharged
after emergency department (ED) management.
Objective: Evaluate the relationship between troponin elevation and outcomes in
patients with AHF who are treated and released from the ED.
Methods: This was a secondary analysis of the Get with the Guidelines to Reduce
Disparities in AHF Patients Discharged from the ED (GUIDED-HF) trial, a randomized, controlled trial of ED patients with AHF who were discharged. Patients with elevated conventional troponin not due to acute coronary syndrome (ACS) were included.
Our primary outcome was a composite endpoint: time to 30-day cardiovascular death
and/or heart failure-related events.
Results: Of the 491 subjects included in the GUIDED-HF trial, 418 had troponin measured during the ED evaluation and 66 (16%) had troponin values above the 99th percentile. Median age was 63 years (interquartile range, 54-70), 62% (n = 261) were
male, 63% (n = 265) were Black, and 16% (n = 67) experienced our primary outcome.
There were no differences in our primary outcome between those with and without
troponin elevation (12/66, 18.1% vs 55/352, 15.6%; P = 0.60). This effect was maintained regardless of assignment to usual care or the intervention arm. In multivariable
regression analysis, there was no association between our primary outcome and elevated troponin (hazard ratio, 1.00; 95% confidence interval, 0.49–2.01, P = 0.994)
Conclusion: If confirmed in a larger cohort, these findings may facilitate safe ED discharge for a group of patients with AHF without ACS when an elevated troponin is the
primary reason for admission.
KEYWORDS

acute heart failure, biological markers, emergency medicine, quality, readmission, transitional
care, troponin

1
1.1

INTRODUCTION
Background

1.2

Importance

The initial ED evaluation for AHF includes measurement of cardiac troponin for diagnostic and prognostic purposes. An elevated troponin in

Acute heart failure (AHF) is a common disease presentation to the

patients with AHF is common and has been widely studied. The preva-

emergency department (ED), resulting in admission rates greater than

lence of troponin elevation depends on the assay, the type and sever-

80%.1,2 As the average age of our population rises, the number of ED

ity of the HF, and presenting symptoms.6 When using a conventional

visits will likely increase from the approximately 670,000 new cases

cardiac troponin T assay, 10.4% of a chronic HF population may have a

seen annually in the United States.3 AHF evaluation and treatment

detectable troponin, whereas the same population tested with a high

begins in the ED but rarely leads to a discharge home for the patient.

sensitivity assay found 92% had a detectable troponin.7,8 Given the

Prior studies suggest patients with AHF who are treated and released

variety of assays and AHF etiologies, the ED physician must frequently

from the ED may have worse outcomes than those who are admitted.4,5

distinguish between an elevated cardiac troponin due to acute coro-

Thus, many patients are admitted for further testing, risk stratifica-

nary syndrome (ACS) and those due to other physiologic processes.9,10

tion, and continued medical care including blood pressure control and

The cause for an elevated cardiac troponin in AHF is twice as

decongestive treatment.

likely to be related to supply demand mismatch and poor diastolic
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perfusion rather than plaque rupture.8 However, an elevated troponin
has been associated with an increased risk for mortality in patients

The Bottom Line

with AHF and this clinical finding often biases the emergency physician
Prior data suggest that patients with acute heart failure and

toward hospital admission even when the remainder of the ED eval-

an elevated troponin have increased mortality and should be

uation is reassuring.11,12 Conversely, other studies suggest troponin

admitted. In this secondary analysis of 491 subjects enrolled

may be of less prognostic significance when measured during the initial

in the GUIDED-HF trial, there was no difference in 30-day

patient presentation.13,14 These studies were inherently biased, how-

cardiovascular death or heart failure related events between

ever, because they evaluated the prognostic significance of troponin in

those with and without elevated troponin (>99th percentile).

patients who were already admitted to the hospital.

These data suggest that some heart failure patients with an
elevated troponin may be safely discharged from the emer-

1.3

gency department.

Goals

We have previously reported the primary outcome of our randomized
trial of a self-care intervention in patients with AHF who were discharged after ED management.15 In this secondary analysis, we com-

admission and whether it was related to AHF and cardiovascular (CV)

pare the 30- and 90-day outcomes of patients with AHF who were dis-

or non-CV death. All events were adjudicated by a clinical event com-

charged from the ED with an elevated troponin to those who were dis-

mittee consisting of two emergency physicians and a cardiologist. The

charged without an elevated troponin.

GUIDED-HF trial was approved by the institutional review board of
each participating institution.

2

METHODS
2.4

2.1

Outcomes

Study design and setting
The primary outcome for this secondary analysis was time to the first

We conducted a secondary analysis of patients with AHF who were dis-

HF-related adverse events within 30 days of ED discharge based on the

charged after ED management and enrolled in the randomized clinical

phone follow-up and chart review conducted by the study coordina-

trial Get with the Guidelines to Reduce Disparities in AHF Patients Dis-

tor blinded to treatment arm. This included unscheduled HF clinic vis-

charged from the ED (GUIDED-HF). This trial evaluated usual care ver-

its with intravenous diuretics given, ED return visits or hospital admis-

sus an intensive ED based self-care strategy. The rationale and design

sions for AHF, and CV-related death. We also evaluated the primary

and primary results for the GUIDED-HF trial have been previously

outcome measured over 90 days. Our safety outcome was time to the

reported.15,16

following events within 90 days of ED discharge: all-cause ED revisit
that includes readmission for ACS, hospitalization, and all-cause death.

2.2

Selection of participants
2.5

Statistical analysis

Patients presenting to the ED with AHF who met the following criteria
were approached for enrollment: prior history of AHF, systolic blood

All patients who had troponin measured in the ED were included for

pressure (BP) >100 mm Hg, no evidence of ACS (based on clinical eval-

analysis. To help standardize troponin values because different assays

uation including history, physical exam, ECG, and troponin), and not on

were used, cardiac troponin was dichotomized and was considered

outpatient inotrope therapy. Patients remained eligible for enrollment

elevated if it was above the 99th percentile site-specific upper ref-

in GUIDED-HF if they had an elevated cardiac troponin that the treat-

erence limit (URL). Troponin results were available to the treating

ing physician felt was not due to ACS. All eligible patients enrolled in

physician. All troponin assays used at the time of this study were

GUIDED-HF were discharged either directly from the ED or after ED-

based on conventional sensitivity assay platforms. The first troponin

based observation.

was used to classify participants. Data summaries are presented as
medians with interquartile ranges (IQR), counts, and proportions, as
appropriate. Wilcoxon rank-sum and Pearson χ2 tests were used to

2.3

Measurements

compare continuous and categorical data between those with elevated and nonelevated troponin values, respectively. Kaplan–Meier

Follow-up telephone encounters were conducted for all patients at 30

(KM) plots together with log-rank tests were used to compare survival

and 90 days after discharge by research staff blinded to the interven-

outcomes by troponin status. Cox proportional hazards models were

tion arm. Outcomes recorded included date of an unscheduled clinic

used to assess the association of survival outcomes and troponin sta-

visit for AHF with intravenous diuretics given, ED revisit, or hospital

tus in the overall cohort and within each treatment arm, adjusting for
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treatment assignment, traditional measures of HF severity including age, sex, ejection fraction (moderate/severe vs normal), systolic
BP, b-type natriuretic peptide level (BNP), estimated glomerular filtration rate (eGFR), and outpatient dose of diuretic. Proportional
hazards assumptions were also checked using the residual-based
method.17 Significance was set a priori at P < 0.05. Missing data were
imputed using predictive mean matching and 10 imputation replications. Adjusting variables with any missingness were imputed, including ejection fraction (moderate/severe vs normal), systolic BP, BNP, and
eGFR. The predictive mean matching was based on the linear predictors and thus was used for categorical variables as well (eg, using multinomial model or logistic regression as the imputation model). We used
aregImpute function in Hmisc R package, which by default uses a draw
from a multinomial distribution with probabilities derived from distance weights for “matching,” where the distance weights are calculated using the tricube function. Records with longer distance (based
on linear predictors of the imputation model) from the target record
will have smaller probabilities of being drawn. Therefore, there was not
a fixed number of donors used for each target variable. We assumed
missing at random for all variables with any missingness. We did not
think any of those variables are likely not missing at random. We drew
plots of imputed values against sequential imputation numbers sepa-

FIGURE 1

Consort diagram

rately for each missing observations and variable. We did not observe
any systematic patterns that suggest the imputation might be problematic. All statistical analyses were conducted using R statistical software
(version 3.5.2).

After adjusting for known measures of HF severity, relative to
patients with a nonelevated troponin, an elevated troponin was not
associated with our primary outcome (adjusted hazard ratio [aHR],
1.00; 95% confidence interval [CI], 0.49–2.01; P = 0.99). The aHR in

3

RESULTS

intervention (aHR, 0.50; 95% CI, 0.10–2.64; P = 0.42) and usual care
arms (aHR, 1.41; 95% CI, 0.59–3.42; P = 0.44) both found no significant

3.1

Baseline characteristics

differences in our primary outcome in those with and without troponin
elevation (Table 3).

There were 491 patients enrolled at 15 sites. Of these, 12 withdrew

BNP (per 50 units) was associated with our primary outcome at 30

consent and 61 did not have a troponin measured, leaving 418 patients

days in the overall cohort (aHR, 1.02; 95% CI, 1.00–1.04; P = 0.01), with

who fulfilled all study criteria (Figure 1). Within this cohort, 66 (16%)

little difference between the intervention (aHR, 1.02; 95% CI, 1.00–

patients had an elevated troponin and 352 (84%) did not. These two

1.05; P = 0.07) and usual care arms (aHR, 1.02; 95% CI, 1.00–1.05;

cohorts were similar with respect to age, sex, and race (Table 1). There

P = 0.06). Estimated GFR (per 1 unit) was shown to have no associa-

were significant differences (P < 0.05) in prior EF, initial creatinine

tion with the primary outcome in the overall cohort (aHR, 0.99; 95%

value, initial systolic BP, ED measures of natriuretic peptides, ACE

CI, 0.98–1.00; P = 0.23) or the intervention arm (aHR, 1.00; 95% CI,

inhibitor use in the ED, and history of MI (Table 1).

0.98–1.02; P = 1.00) but did have an association in the usual care
arm (aHR, 0.98; 95% CI, 0.97–1.00; P = 0.03). Outpatient diuretic
dose in furosemide equivalents (per 20 mg) was not associated with

3.2

Primary outcome at 30 days

the primary outcome in the overall cohort (aHR, 0.94; 95% CI, 0.85–
1.03; P = 0.19) or the intervention arm (aHR, 1.02; 95% CI, 0.90–1.14;

The primary outcome occurred in 16% (n = 67) of patients (Table 2).

P = 0.79) but was associated with the primary outcome in the usual care

One CV-related death was reported in the nonelevated troponin

arm (aHR, 0.81; 95% CI, 0.68–0.97; P = 0.02) (Table 3).

group. Compared to those with nonelevated troponin values, subjects with an elevated troponin did not have an increased proportion
of events in our primary outcome (12/66, 18.1% vs 55/352, 15.6%;
P = 0.60). This difference was similar regardless of assignment to the

3.3
Primary outcome and safety outcomes at
90 days

intervention or usual care arm (Table 2). From the KM plot, the probability of being event-free within 30 days also did not differ by troponin

The primary outcome at 90 days occurred in 35% (n = 147) of patients.

status (Figure 2).

Subjects with an elevated troponin had a trend toward an increase in
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TA B L E 1

Baseline characteristics

Combined (N = 418)

Non-elevated Tn
(N = 352)

Elevated Tn (N = 66)

Male

62% (261)

62% (217)

67% (44)

Female

38% (157)

38% (135)

33% (22)

American Indian/Alaska Native

0% (1)

0% (1)

0% (0)

Asian

0% (0)

0% (0)

0% (0)

No.
Gender at birth

Race

418

0.44

418

0.118

Black/African American

63% (265)

61% (215)

76% (50)

Hawaiian/Pacific Islander

0% (2)

0% (1)

2% (1)

White non-Hispanic

33% (136)

34% (121)

23% (15)

White Hispanic

2% (8)

2% (8)

0% (0)

Multi-racial

0% (0)

0% (0)

0% (0)

Other

0% (0)

0% (0)

0% (0)

Declined to disclose

1% (6)

2% (6)

0% (0)

62.94 (54.18, 70.01)

63.09 (53.8, 69.95)

61.82 (55.71, 71.43)

Age at consent

418

Prior ejection fraction

394

Normal (>X%)

0.929
0.003

40% (159)

Moderate/severe (≤Y%)

P

44% (144)

24% (15)

60% (235)

56% (187)

76% (48)

Prior ejection fraction missing indicator

418

6% (24)

6% (21)

5% (3)

0.649

Initial BUN value (mg/dL)

416

19 (14, 27)

18 (14, 26)

21 (15, 29)

0.099

418

0% (2)

1% (2)

0% (0)

0.539

416

1.15 (0.9275, 1.44)

1.13 (0.9, 1.4)

1.275 (1.042, 1.722)

0.004

418

0% (2)

1% (2)

0% (0)

0.539

417

143 (126, 165)

141 (124, 163)

153.5 (136.8, 183.5)

<0.001

418

0% (1)

0% (1)

0% (0)

0.665

Initial BUN value missing indicator
Initial creatinine value (mg/dL)
Initial creatinine value missing
indicator
Initial systolic blood pressure (mm Hg)
Initial systolic blood pressure missing
indicator
Initial BNP value (pg/mL)
Initial BNP value missing indicator
Initial NT-proBNP value (pg/mL)
Initial NT-proBNP value missing
indicator

194

521.5 (179.8, 1180)

461 (155, 995)

1048 (495, 1500)

0.003

418

54% (224)

53% (187)

56% (37)

0.661

209

1140 (324, 3500)

898 (297.8, 3081)

2998 (1152, 6870)

<0.001

418

50% (209)

51% (178)

47% (31)

0.592

Initial troponin I (ng/mL)

398

0.025 (0.012, 0.04)

0.02 (0.012, 0.03)

0.06 (0.05, 0.09)

<0.001

Initial troponin T (ng/mL)

20

0.01 (0.01, 0.0325)

0.01 (0.01, 0.03)

0.14 (0.085, 0.27)

0.016

Beta blocker in the ED

406

9% (38)

9% (30)

13% (8)

0.322

418

3% (12)

3% (9)

5% (3)

0.375

ACEi in the ED

418

11% (44)

9% (31)

20% (13)

0.008

Diuretic in the ED

418

89% (371)

89% (314)

86% (57)

0.503

ACEi at discharge

413

43% (179)

43% (150)

45% (29)

0.821

418

1% (5)

1% (4)

2% (1)

0.795

409

20% (81)

20% (70)

17% (11)

0.567

418

2% (9)

2% (7)

3% (2)

0.593

Beta blocker in the ED missing
indicator

ACEi at discharge missing indicator
ARB at discharge
ARB at discharge missing indicator
Beta blocker at discharge
Beta blocker at discharge missing
indicator

415

76% (314)

76% (265)

75% (49)

0.955

418

1% (3)

1% (2)

2% (1)

0.403

(Continues)

26881152, 2022, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/emp2.12695, Wiley Online Library on [06/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

5 of 10

FERMANN ET AL .

TA B L E 1

FERMANN ET AL .

(Continued)

No.

Combined (N = 418)

Non-elevated Tn
(N = 352)

Elevated Tn (N = 66)

P

Diuretic at discharge

418

89% (373)

90% (316)

86% (57)

0.412

Diuretic dose at discharge
(Lasix-equivalents)

418

40 (20, 80)

40 (20, 80)

40 (20, 80)

0.23

Hx Diabetes

418

46% (192)

46% (162)

45% (30)

Hx COPD

418

Yes

34% (144)

36% (128)

24% (16)

No

65% (270)

62% (220)

76% (50)

Unknown

1% (4)

1% (4)

0% (0)

Yes

31% (128)

28% (98)

45% (30)

No

68% (285)

71% (250)

53% (35)

1% (5)

1% (4)

2% (1)

Hx MI

0.932
0.099

418

0.015

Unknown
Hx CKD

417

0.37

Yes

27% (112)

26% (90)

33% (22)

No

73% (303)

74% (259)

67% (44)

Unknown

0% (2)

1% (2)

0% (0)

Hx CKD missing indicator

418

0% (1)

0% (1)

0% (0)

0.665

Hx Hypertension

418

93% (390)

93% (327)

95% (63)

0.446

Prior ejection fraction

391

0.006

Not reported

2% (9)

2% (7)

3% (2)

Normal

39% (152)

42% (138)

22% (14)

Moderate

30% (116)

27% (90)

41% (26)

Severe

29% (113)

28% (93)

32% (20)

Unknown

0% (1)

0% (0)

2% (1)

6% (27)

7% (24)

5% (3)

Hx EF missing indicator

418

0.491

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NT-proBNP, N-terminal prohormone b-type
natriuretic peptide; Tn, troponin.

TA B L E 2

Event rates of the primary outcomea at 30 days and their components for overall and stratified by Tn and intervention arms
Overall
No
(N = 352)

Intervention Arm
Yes
(N = 66)

Combined
(N = 418) P

Usual Care Arm

No
(N = 176)

Yes
(N = 28)

Combined
(N = 204) P

No
(N = 176)

Yes
(N = 38)

Combined
(N = 214) P

Primary outcome 16% (55)
(30 days)

18% (12) 16% (67)

0.603

14% (25)

14% (4)

14% (29)

0.991

17% (30)

21% (8)

18% (38)

0.558

HF clinic visit

2% (1)

0.184

1% (1)

0% (0)

0% (1)

0.689

0% (0)

3% (1)

0% (1)

0.031

ED revisit for HF 15% (49)

0% (1)

17% (11) 15% (60)

0.649

13% (22)

14% (4)

13% (26)

0.827

17% (27)

19% (7)

17% (34)

0.755

Hospital
13% (44)
admission for
HF

12% (8)

13% (52)

0.856

12% (21)

11% (3)

12% (24)

0.821

14% (23)

14% (5)

14% (28)

0.925

CVD

0% (0)

0% (1)

0.665

0% (0)

0% (0)

0% (0)

1% (1)

0% (0)

0% (1)

0.641

0% (1)

0% (2)

Abbreviations: CVD, cardiovascular death; ED, emergency department; HF, heart failure; IV, intravenous; No, nonelevated Tn; Tn, troponin; Yes, elevated Tn.
a
Unscheduled clinic visit with IV diuretic, HF-related ED visit or hospitalization, or CVD.
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F I G U R E 2 Kaplan–Meier curve: primary outcome at 30 days. The
upper limit of normal (ULN) was defined as the local laboratory’s 99th
percentile value for cardiac troponin

F I G U R E 3 GUIDED-HF study with 30 and 90-day primary
outcomes and 30-day safety outcome

events (30/66, 45.5%) compared to those with nonelevated troponin

measures of HF severity, the results for the 90-day safety outcome did

values (117/352, 33.2%; P = 0.06) due to differences in ED revisits and

not differ significantly between those with and without an elevated tro-

hospital admission for AHF. After adjusting for potential confounding

ponin. An elevated troponin was not associated with the safety out-

variables there were no differences in the overall cohort or by treat-

come in the overall cohort (aHR, 0.99; 95% CI, 0.69–1.42; P = 0.97), the

ment arm. An elevated troponin was not associated with 90-day HF-

intervention arm (aHR, 0.91; 95% CI, 0.50–1.64; P = 0.74), or usual care

related adverse events in the overall cohort (aHR, 1.03; 95% CI, 0.63–

arm (aHR, 1.14; 95% CI, 0.70–1.86; P = 0.59) (Supporting Information

1.69; P = 0.90), the intervention arm (aHR, 1.00; 95% CI, 0.46–2.15;

Table S2).

P = 1.00), or usual care arm (aHR, 1.22; 95% CI, 0.66–2.26; P = 0.52)
(Figure 3 and Supporting Information Table S1).
The 90-day safety outcome occurred in 58.4% (n = 244) of patients.

4

LIMITATIONS

Compared to those with nonelevated troponin values, subjects with
an elevated troponin did not have an increased proportion of events

Although we report the first prospective evaluation of patients dis-

(205/352, 58.2% vs 39/66, 59.1%; P = 0.90). After adjusting for known

charged from the ED with an elevated troponin, there are limitations

TA B L E 3

Cox regression results for the primary outcomea at 30 days for overall and stratified by Tn and intervention arms
Overall

Intervention

Usual care

Covariate

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Elevated troponin (ref = normal troponin)

1.00

0.49, 2.01

0.99

0.50

0.10, 2.64

0.42

1.41

0.59, 3.42

0.44

Intervention (ref = usual care)

0.72

0.43, 1.20

0.20

Age (per 5 y)

1.05

0.95, 1.17

0.33

1.17

0.99, 1.38

0.06

0.95

0.82, 1.11

0.54

Female (ref = male)

0.92

0.54, 1.57

0.77

0.78

0.34, 1.77

0.55

0.85

0.43, 1.71

0.66

Moderate/severe prior EF (ref = normal)

0.70

0.39, 1.26

0.24

0.66

0.27, 1.64

0.37

0.58

0.25, 1.33

0.20

eGFR (per 1 unit)

0.99

0.98, 1.00

0.23

1.00

0.98, 1.02

1.00

0.98

0.97, 1.00

0.03

ED dystolic BP (per 5 units)

0.97

0.92, 1.02

0.18

1.00

0.92, 1.07

0.93

0.93

0.87, 1.01

0.07

BNP (per 50 units)

1.02

1.00, 1.04

0.01

1.02

1.00, 1.05

0.07

1.02

1.00, 1.05

0.06

Outpatient diuretic lasix-equivalents dose (per 20 mg)

0.94

0.85, 1.03

0.19

1.02

0.90, 1.14

0.79

0.81

0.68, 0.97

0.02

Abbreviations: BP, blood pressure; BNP, B-type natriuretic peptide; CI, confidence interval; ED, emergency department; EF, ejection fraction; eGFR, estimated
glomerular filtration rate; HR, hazard ratio; Tn, troponin.
a
Unscheduled clinic visit with IV diuretic, HF-related ED visit or hospitalization, or CVD.
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to consider. This is a specific population of patients with AHF deemed

of subjects. These patients were not discharged from the ED like our

safe for discharge and were considered unlikely to have ACS by the

cohort, but troponin elevations in the ED were associated with longer

treating physician. Therefore, our cohort cannot be generalized to all

in-hospital length of stay, more episodes of worsening HF in the hospi-

patients presenting with AHF in the ED. Although all troponin val-

tal, and higher in-hospital mortality. These associations were not sus-

ues were conventional sensitivity, the troponin assay used varied at

tained when the patients were followed for 30 and 180 days after hos-

each site, reflecting the pragmatic and multicenter nature of GUIDED-

pital admission.19 A recent secondary analysis of the same ASCEND-

HF. Although the analysis treated troponin as a dichotomous vari-

HF database found 2% of patients who were admitted for AHF had

able above the site-specific 99th percentile, assessment of outcomes

sudden cardiac death (SCD) after hospital discharge. In a multivariable

related to different assays, or treating troponin as a continuous vari-

model, elevated in-hospital troponin was not associated with SCD, Ven-

able, may also be of interest. The authors acknowledge higher troponin

tricular Tachycardia (VT)/Ventricular Fibrillation (VF), or resuscitated

elevations are more likely to be associated with ACS and those patients

SCD after discharge through day 30.20

were less likely to be included in the GUIDED-HF trial because of the

Prior studies suggest over 80% of patients who present to the ED

previously described inclusion and exclusion criteria. We also acknowl-

with AHF are admitted. Many of the AHF risk stratification tools incor-

edge clinicians may have used several means to determine whether an

porate troponin as a predictor and all recommend those patients with

isolated troponin elevation was due to ACS, including comparing tro-

an elevated troponin should be admitted to the hospital.21–25 Thus, the

ponin elevations to values from prior visits and measuring changes in

cohort we studied with an elevated troponin most often is admitted

troponin during the index ED visit. The degree to which this led to con-

to the hospital. Most of these tools incorporate a major adverse car-

firmation bias is unknown because the determination of ACS was left

diac event outcome but the duration of follow-up often varies. How-

to the treating physician and not adjudicated.

ever, the context of the troponin elevation and whether it can be mod-

High-sensitivity (hs) troponin was cleared for use in the United

ified with treatment, other than for ACS, is unclear. When evaluating

States toward the end of subject recruitment in GUIDED-HF and there

the prognostic significance of an elevated Tn in our cohort, where ACS

has been much interest regarding the prognostic value of detectable

was excluded, there were no appreciable difference in the 30-day pri-

levels that do not exceed the 99th percentile. A recent study of hs-

mary outcome. Although we identified a trend toward significance in

troponin in AHF shows similar findings to those in our study, but fur-

our unadjusted of the primary outcome at 90 days (P = 0.06), this dif-

ther study of hs-troponin in AHF subjects is necessary.2 The lack of

ference was no longer present in our adjusted model (see Supporting

serial troponin quantification is an additional limitation, particularly in

Information Tables S1 and S2). ED revisit and HF clinic visits appear to

determining whether troponin concentrations increase over time and

contribute most to this trend rather than 90-day CV mortality or HF

may be suggestive of acute coronary syndrome rather than AHF. Sub-

hospitalizations. The cause of troponin elevation is important to con-

jects were not enrolled in GUIDED-HF if the clinical picture suggested

sider as we aim to identify patients with modifiable risk where a hos-

ACS was a cause of presenting symptoms, and this clinical picture often

pital admission or close outpatient follow-up after ED discharge could

includes serial troponin (Tn) evaluation in the ED. Finally, our sample

impact near-term events. Those with a troponin elevation related to

size was relatively small and replication of our results in a larger cohort

ACS may need further evaluation and treatment requiring hospitaliza-

of ED patients with elevated troponin values would be informative.

tion. Patients with slight troponin elevations not due to ACS may be a
different population than those included in large inpatient cohorts like
ASCEND-HF where troponin elevation was associated with ACS and

5

DISCUSSION

unfavorable outcomes, particularly in the hospital.19 Importantly, troponin is just one component of the overall risk-stratification process

This secondary analysis is the first prospective study to evaluate the

and its interpretation is often dichotomous (elevated or not elevated)

prognostic significance of an elevated troponin in patients with AHF

in the ED setting. When used as a continuous variable, the magnitude of

discharged after ED-based management. We report several important

elevation often drives decision-making. The median cTnI value in those

findings. First, 66 patients with troponins above the 99th percentile

with elevated troponin was 0.06 ng/mL with an IQR of 0.05-0.09 ng/mL,

were discharged from the ED. Importantly, they did not have increases

a range most clinicians would describe as a “low level” elevation. The

in CV-related or non–CV-related events compared to those with nonel-

magnitude of the elevation may have influenced the clinician’s decision

evated troponin values over 30 days. Second, the overall event rate in

to not suspect ACS. Disposition decision-making may need to be revis-

those discharged from the ED is lower than first reported,4 is similar to

ited and account for all modifiable risk factors including amount of con-

recent reports in a large healthcare system in the United States,18 and

gestion, patient engagement, and a safe transition plan to the outpa-

was similar in the intervention and usual care arms. Third, traditional

tient setting.

risk factors for adverse events in HF inpatients and stable outpatients,

Although our investigation suggests troponin may not be associated

such as renal function and natriuretic peptides, were also associated

with an increased risk of adverse events in ED patients who are oth-

with HF adverse events in our cohort of patients discharged from the

erwise suitable for discharge after ED-based management, other tra-

ED.

ditional markers of increased risk were associated with increased CV

In the ASCEND-HF trial, a conventional troponin was undetectable

mortality and adverse events in our population including eGFR and

in only 22% of subjects and elevated above the 99th percentile in 50%

BNP. Across the spectrum of HF subtypes, CKD and worsening renal
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function has been associated with all-cause mortality and CV-related
adverse events during hospitalization, shortly after discharge (30-day
and 90-day) and long-term follow-up (1 and 5 years).26 BNP similarly

9.

demonstrates the ability to predict short- and long-term mortality and
CV-related adverse events.27
Patients discharged after ED-based management had a low overall
30-day event rate in this secondary analysis of GUIDED-HF. An elevated conventional troponin was not associated with 30-day adverse

10.
11.

outcomes. If confirmed in a larger cohort, these findings may facilitate
safe ED discharge for a select group of patients with AHF when an elevated troponin is the primary reason for admission.

12.
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